Moody’s affirms ‘A2’ rating on WakeMed

Moody’s Investors Service affirmed its “A2” long-term rating on Raleigh, N.C.-based WakeMed, affecting about $390 million of debt.

Advertisement

The affirmation is a result of several factors, including the health system’s favorable service area, growing cash flow margins and consistent operating performance.

The outlook is stable, reflecting Moody’s expectation that the health system’s cash flow will remain strong as WakeMed invests in facilities and services to stay competitive.

More articles on healthcare finance:
Missouri to hospitals: Contract with 3 managed Medicaid insurers or face 10% payment cut
2 Arkansas hospitals accuse EMS provider of balance billing
13 latest hospital credit rating downgrades

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.